Introduction
Effective therapy for castrate-resistant metastatic prostate cancer is much needed as it remains an incurable disease. Prostate cancer metastases occur earliest and most frequently-though not exclusively-in bone and are commonly associated with an osteoblastic response. [1] [2] [3] [4] Because of this phenomenon, great effort has gone into determining its biological basis with the aim of identifying a suitable treatment strategy. One investigational therapy designed to address this involves blockade of the endothelin signaling axis with ETA antagonists. Endothelin-1 (ET-1), a 21 amino acid peptide, was initially isolated as a potent vasoconstrictor from porcine aortic endothelial cells and has now been identified in many tissues throughout the body, including the prostate where it is highly expressed. 5, 6 It is a member of a family of three related peptides, ET-1, -2 and -3. 7 Endothelins signal through two G-protein coupled receptors ETA and ETB also expressed in a variety of cell types. ETA binds ET-1 and ET-2 with highest affinity whereas ETB binds each of the endothelins with equal but lower affinity than ETA. Receptor activation may directly engage a variety of downstream signaling mechanisms leading to cell contraction, Key words: prostate cancer, atrasentan, endothelin-1, metastasis, bioluminescence imaging, bone Abbreviations: BLI, bioluminescent imaging; ET-1, endothelin-1; ETA, endothelin A receptor; ETB, endothelin B receptor; VEGF, vascular endothelial growth factor; MVD, microvessel density migration, proliferation and survival and/or enhance signaling through receptor tyrosine kinases such as the epidermal growth factor receptor. 8, 9 Mice null for either ET-1 or ETA display similar phenotypes, severe craniofacial and cardiovascular defects, and die immediately after birth indicating that the ET-1/ETA pathway is crucial for various developmental processes. 10, 11 The endothelin pathway has been implicated in cancer. 12 Elevated levels of ET-1 expression have been documented in prostate and other cancers. 13, 14 Several indirect lines of evidence indicate that ET-1 may specifically be involved in the osteoblastic lesions characteristic of prostate cancer metastasis to bone: ET-1 stimulates osteoblasts to form bone in organ cultures; intratibial injection of ET-1-overexpressing WISH (HeLa) cells elicited osteoblastic lesions which could be inhibited by an ETA antagonist; and atrasentan (ABT-627), blocked the development of osteoblastic, but not osteolytic, bone tumors in a model of breast cancer metastatic colonization. [15] [16] [17] In the latter study, it is important to note that atrasentan did not inhibit the growth of orthotopic tumors in the mammary fat pads. These findings are consistent with a "vicious cycle" model in which ET-1 acts in the bone microenvironment to promote osteoblastic lesions that, Advanced prostate cancer frequently metastasizes to bone and remains an incurable disease. One recent experimental therapy involves endothelin receptor A (eTA) antagonists (e.g., atrasentan). Clinical results to date have been mixed, with atrasentan not meeting its primary endpoints in a phase III trial. It remains an open question whether some patients might benefit from this therapy, while others may not. preclinical data supports the concept that the endothelin signaling axis may be particularly important for tumor growth in bone, but the extent to which it is involved in metastatic colonization of other organ sites in prostate cancer remains unclear. here we evaluate the efficacy of atrasentan in a mouse model of prostate cancer metastatic colonization. Using bioluminescence imaging, we show that atrasentan does inhibit tumor growth in, but not the initial colonization of, bony sites in intracardially-injected 22Rv1 prostate cancer cells. however, atrasentan shows little efficacy in soft tissues such as adrenal gland or liver. Our studies show that whether atrasentan exhibits significant overall antitumor efficacy and survival benefit depends on the presence of bone metastasis evident in that animal. Though in contrast to previous findings efficacy is apparent in a prostate tumor model that elicits mixed osteoblastic/osteolytic lesions. These data confirm the notion that atrasentan may exhibit selective activity against prostate cancer bone metastasis, mirroring clinical findings, and suggest that the role of endothelin signaling in bone metastasis may be more complex than previously appreciated. The model described here may provide a valuable tool for unraveling this complexity.
colonization. We previously developed the model based on intracardiac injection of luciferase-expressing 22Rv1 luciferase cells which form tumors in bone as well as soft tissue sites, such as liver and adrenal gland. 38 We administered atrasentan via an oral route just prior to injection of tumor cells. Atrasentan did not significantly affect whole body tumor burden as judged by bioluminescence imaging. Interestingly however, imaging studies revealed that cells colonizing bone grew initially before regressing, sometimes quite rapidly, whereas tumors growing in softtissue sites in the same animal grew unperturbed by treatment. Our results show that atrasentan specifically inhibits the growth, but not initial colonization, of bone metastases while not inhibiting the growth of tumors in a variety of soft tissue sites. Thus, our model reflects certain aspects of the clinical activity of atrasentan and may therefore be instructive to further elucidate the mechanism-of-action of ETA antagonists as well as to understand the role of ET-1 in the biology of prostate cancer bone metastasis.
Results
Atrasentan does not significantly affect overall tumor burden and survival of mice intracardially injected with 22Rv1-luciferase cells. To evaluate the efficacy of atrasentan in a mouse model of prostate cancer metastasis we employed a model involving 22Rv1-luciferase cells previously developed in our lab. 38 We first determined whether atrasentan had any direct cytotoxic effects on 22Rv1-luciferase cells in vitro and determined that at doses up to 10 µM, well above pharmacologically relevant levels in vivo, there was no significant toxicity noted with up to 5 d of exposure (Fig. 1A) . This is consistent with our previous findings that 22Rv1 cells express very little ETA and do not secrete a sufficient quantity of ET-1 for autocrine activation of this receptor in vitro. 31 Because we were interested in the possibility that atrasentan might block early events in metastatic colonization, we initiated treatment with atrasentan 3 d prior to tumor cell injection. Animals were dosed via drinking water and average water consumption was measured to estimate the dose received. This treatment regimen resulted in an estimated 10 mg/kg/day atrasentan dose. This regimen was used in prior studies and demonstrated pharmacologically relevant plasma atrasentan levels in mice. 17 We then injected 22Rv1-luciferase cells intracardially into SCID mice. Injections were done blinded to treatment groups. Bioluminescence imaging immediately following injections was used to estimate injection success by measuring the ratio of signal in the thoracic cavity to that in the whole body (T/WB ratio) as described previously. 38 There were no significant differences in the T/WB ratio between the treatment groups indicating an equivalent level of injection success (Fig. 1B) . We monitored water intake and body weight throughout the experiment and found no difference between the groups, indicating the mice are all receiving similar doses of drug and that this treatment regimen of atrasentan is not overtly toxic in mice (data not shown and Fig. 1C, respectively) .
Following injection of tumor cells, we imaged these mice on a weekly basis to monitor tumor growth and colonization patterns. in turn, creates an environment supportive for tumor growth. 18 However, in the Scid-hu model, where prostate cancer cells are injected directly into human fetal bone explants, atrasentan alone was ineffective at blocking C4-2b prostate tumor growth; though it did enhance the antitumor efficacy of docetaxel. 19 Other studies indicate that ET-1 may also play a role in cancer beyond bone metastasis. ET-1 has been repeatedly shown to mediate survival and/or proliferation in cell-based assays, including prostate cancer cells. 13, [20] [21] [22] ET-1 has been shown to have direct angiogenic activity on cultured endothelial cells which enhanced the effect of vascular endothelial growth factor (VEGF) and is mediated primarily by ETB. 23, 24 In vivo studies have yielded conflicting results, with ET-1 failing to induce angiogenesis in chick embryo chorioallantoic membrane and rat sponge models and inducing angiogenesis, via ETA, in a rat cornea model and, when combined with VEGF, in the matrigel plug and chick embryo chorioallantoic membrane assays. [24] [25] [26] [27] [28] ET-1, via ETA, has been shown to upregulate VEGF in normoxic ovarian carcinoma cells by stabilization of the VEGF regulatory protein HIF-1α and has been correlated with VEGF expression and microvessel density (MVD) in breast and ovarian carcinomas. 25, 29, 30 However, whether ET-1 plays either a direct or indirect role in angiogenesis of prostate cancer has not been fully investigated. Finally, our recent studies have shown that high-level ET-1 exerts deleterious effects on prostate tumor growth via its vasoconstrictive effects on tumor-feeding arterioles. 31 Thus, ET-1 may, in principle, be involved in a variety of tumor-promoting and inhibiting activities in prostate cancer, alternatively, or in addition to the bonespecific role described above.
The potential connection of the endothelin pathway to essential hypertension led to robust pharmaceutical development of ET receptor antagonists resulting in a number of orally bioavailable drugs. 32 Based on some of the preclinical findings mentioned above, clinical trials with atrasentan, an ETA-selective antagonist, were initiated. Large, double-blinded, placebo-controlled Phase III clinical trials in patients with metastatic and non-metastatic, castrate-resistant prostate cancer has shown that atrasentan did not significantly delay time to disease progression or overall survival. 33, 34 However, atrasentan treatment did significantly affect secondary endpoints such as PSA progression and serum markers of bone turnover and its toxicity profile was relatively mild and consistent with its expected vasodilatory effect, indicating its biologic activity. In some studies, atrasentan also reduced bone pain, consistent with a potential role for ET-1 in nociception. 35 A recently published Phase II study on the ETA-selective antagonist ZD4054 in patients with mildly symptomatic bone metastases and castrate-resistant prostate cancer also did not affect time to progression, but did significantly improve overall survival. 36 The basis for these seemingly discrepant findings remains unknown. Additional trials involving atrasentan in combination with docetaxel are ongoing. 37 Because significant questions remain about both the mechanism(s) by which ET-1 may be involved in prostate cancer progression and the clinical utility of ETA-selective antagonists in metastatic prostate cancer, we undertook a preclinical evaluation of atrasentan in a mouse model of prostate cancer metastatic osteoblasts to promote bone formation, a process which in turn promotes a microenvironment conducive for tumor growth. 18 This suggests that ETA on osteoblasts is a key therapeutic target and that ETA blockade is likely to specifically affect bone metastases, but not growth at other organ sites. Alternatively, ETA receptors are present on prostate cancer cells, as well as other cells that may contribute to tumor growth, and other data suggests a role for ET-1 in cell proliferation, survival and angiogenesis. The latter would predict that ETA blockade could affect prostate cancer growth in soft tissue sites of metastasis.
Although clinical trials with ETA antagonists' atrasentan and ZD4054 have yielded mixed results to date in terms of time 20/23 vehicle-treated mice and 18/23 atrasentan mice displayed tumor growth by 8 w ( Fig. 2A and B) . Whole body tumor burden trended downward in atrasentan-treated mice, but did not reach significance (Fig. 2C , p = 0.0957). Further, atrasentan-treated mice trended toward enhanced survival when compared to vehicle treated mice (Fig. 2D , p = 0.1663), but again, this did not reach the significance threshold. Because this outcome was somewhat unexpected given previous preclinical studies with atrasentan, we considered the possibility that the tumor distributions between the groups might have been skewed and therefore might influence the findings. 17 We plotted the numbers of animals with no tumors, the number of bone tumors (signal observed in craniofacial region and leg bones at any point during the study) and the number of soft-tissue sites represented in the control and atrasentan groups ( Table 1) . We observed no significant difference in tumor distribution between the two groups for soft tissue (27/34, -test) . This data supports the T/WB ratios indicating equivalent tumor cell injection efficacy between the groups and suggests that treatment with atrasentan does not influence the colonization frequency or pattern of 22Rv1 cells in mice.
Atrasentan inhibits growth of prostate cancer in bone but not soft tissues. To further evaluate our findings, we investigated the potential site-specific effects of atrasentan in the treatment group. Interestingly, we observed a rapid regression of a tumor in the craniofacial region of an atrasentan-treated mouse, while in the same animal, an adrenal tumor continued to grow (Fig.  3A) . Indeed, this pattern was typical for tumors growing in bone in atrasentan-treated mice (Fig. 3B) . This suggested that atrasentan might preferentially be inhibiting prostate tumor growth in bone. Therefore, we measured the growth of tumors in bone and at extrathoracic soft-tissue sites. This analysis showed that atrasentan was significantly inhibiting prostate tumor growth in bone, but not soft tissues (Fig. 3C and D) . Interestingly, the effect of atrasentan was delayed, that is, after an initial period of growth tumors often exhibited rapid and dramatic regression (Fig. 3B) . This indicates that atrasentan does not effect the initial colonization, early survival or initial growth of prostate cancer cells in bone. To determine if atrasentan would exhibit an effect on overall tumor growth and survival in the subset of mice that exhibited bone metastasis, we compared seven vehicle and seven atrasentan treated mice that displayed bone metastases (Fig. 4) . This subset analysis showed that atrasentan significantly reduced overall tumor burden (Fig. 4A-C) and increased survival (Fig. 4D) .
Discussion
A prevailing rationale for ETA antagonists as therapy in advanced prostate cancer is that ET-1 secreted by prostate cancer cells primes a "vicious cycle" in which ET-1 acts on resident atrasentan effectively blocked the osteoblastic effects of tumor growth in bone. 17 Whether atrasentan affected tumor growth at soft tissue sites in the intracardiac injection model was not commented on in this study, however, atrasentan did not affect the growth of ZR-75-1 cells directly inoculated into the mammary fat pad. Because the hypothesis that ETA antagonists might be specifically active in inhibiting prostate tumor growth in bone versus soft tissue sites had not been specifically investigated in a preclinical model of prostate cancer metastasis, we undertook the studies described in this report.
First, we found that atrasentan, at doses well above pharmacological relevance did not affect the viability of 22Rv1-luciferase cells in vitro. This is consistent with our prior findings of low ETA expression in this cell line and insensitivity to the cell growth promoting effects of ET-1. 31 This finding is important as it indicates that ETA blockade will not directly affect 22Rv1-luciferase cell proliferation or survival, though we cannot formally exclude the possibility that this mechanism might be involved when the cells are placed in vivo. Employing a model of prostate cancer metastasis previously developed by our lab based on 22Rv1-luciferase cells, we evaluated the efficacy of atrasentan treatment. Our study design involved pre-treating the animals with atrasentan before systemic tumor cell inoculation because we were interested in the possibility that atrasentan might inhibit the earliest steps of metastatic colonization such as extravasation or initial survival to progression and overall survival, there is consistent evidence that treatment with these drugs positively affects biomarkers of bone turnover, supporting the concept that ETA antagonists are active in bone. 33 However, this does not clarify whether treatment specifically blocks tumor growth in bone versus soft tissue sites. In both of the most advanced trials involving atrasentan and ZD4054 treatment did not delay time-to-progression. 33, 36 From the data presented, it is not clear to what extent disease progression in patients receiving ETA antagonists resulted from progression in bone, suggesting a weak or complex effect of ETA antagonists in blocking bone tumor growth, versus progression at other organ sites. Prior preclinical studies involving intracardiac injection of osteoblastic ZR-75-1 breast cancer cells showed that Tumor distribution was compared between vehicle and atrasentan treated mice. Multiple tumors were observed and counted for each mouse, including the same tissue site if they were from two separate anatomical locations (e.g., craniofacial region and femur).
soft tissues, even when those tumors are present together in the same animal. A major advantage of our study is that we could monitor the kinetic effects of tumor response to atrasentan by serial imaging. Interestingly, we found that the response to atrasentan in bone was not apparent for about 4 w of treatment and then quite rapid, with the bioluminescence signal falling to near background levels over the course of 1-2 w. The mechanism underlying this unusual response is unclear at present and would not have been observed in earlier experiments involving atrasentan treatment of the ZR-75-1 breast cancer model because bone phenotypes were evaluated at a terminal endpoint. 17 While our data are supportive of the hypothesis that atrasentan targets ETA on osteoblasts to to tumor cells at different tumor sites. However, this proved not to be the case as atrasentan treatment did not significantly affect either the overall numbers of tumors that formed or the distribution of tumors. When we analyzed whole-body tumor growth and survival, although there was a positive trend, atrasentan did not significantly affect either of these variables. However, further analysis revealed that atrasentan did significantly inhibit the growth of tumors in bone, but not soft tissues. When the subset of mice that presented with bone tumors were analyzed, atrasentan showed efficacy both in terms of whole body tumor growth (due to the portion of the signal attributable to bone in those animals) as well as survival. Thus, these data confirm the hypothesis that atrasentan effectively blocks tumor growth in bone, but not in the possibility that ETA blockade somehow augments an innate immune response in the scid mouse host's bone that ultimately leads to tumor regression at that site, but a plausible mechanism to account for this is not readily apparent. Future studies will be aimed at determining the mechanism(s) by which ETA blockade specifically disrupts prostate tumor growth in bone.
Our results are interesting to consider in light of the mixed results from clinical trials with atrasentan and ZD4054. In the Phase III trials with atrasentan, there was no significant effect on either time to progression or overall survival. 33, 34 A key issue in these studies was that progression was assessed primarily by serial bone scans which has been noted as a potential confounding factor in this study. 33 Our data would suggest the possibility that atrasentan treatment may not be effective in treating the initial stages of tumor growth in bone, as well as being ineffective in treating tumors in soft tissues. Nascent tumors growing in bone may be unaffected by atrasentan treatment and score positive in a bone scan; and thus would have indicated disease progression and removal of the patient from the trial even if continued treatment may have ultimately forestalled tumor growth. Discontinuation of treatment at trial sites in the United States may have contributed to poor outcome. 34 In contrast, in ZD4054 Phase II trial, patients were selected with pre-existing, mildly symptomatic bone metastases and while there was no effect on time to disease progression, as judged by clinical progression, pain requiring opioids, and progressive soft-tissue metastasis; there was a significant effect on overall survival although this conclusion is disrupt a paracrine signaling network specifically in bone; the mechanism by which this disruption ultimately affects tumor growth is not known. As mentioned above, in our model, atrasentan treatment does not disrupt initial colonization and growth of prostate tumors in bone. Moreover, an important difference from the previously cited study involving ZR-75-1 breast cancer cells is that 22Rv1-luciferase cells elicit a mixed osteolytic/ osteoblastic phenotype in bone, with the lytic phenotype predominating. 38, 39 Therefore, the efficacy of atrasentan treatment in prostate cancer may not depend strictly on its effects disrupting an overtly osteoblastic phenotype. An alternative possibility is that ETA inhibition in osteoblasts results in a blockade of tumor angiogenesis in bone such that initial tumor growth proceeds to a point where it depends on angiogenesis and then collapses. Consistent with this possibility is that osteogenesis and angiogenesis are coupled in normal bone growth and osteoblasts are known to secrete angiogenic factors such as VEGF in response to stimuli such as 1,25-dihydroxyvitamin D3, PTHrP and IGF-1. [40] [41] [42] Towards this end, bone metastases from various tumors show increased microvessel density compared to normal bone with a concomitant increase in ET-1 and ETA immunostaining. 43 Moreover, ET-1 has been shown to induce VEGF in some cell types via ETA, although one study indicates that it may inhibit VEGF production in osteoblasts. 30, 44, 45 A direct effect of atrasentan on endothelial cells is unlikely because endothelial cells do not express ETA and tumor angiogenesis is apparently unperturbed at sites other than bone. It is also worth considering stocks were prepared fresh weekly. Water bottles were weighed to evaluate the amount of drinking water consumed on a weekly basis. Mice were injected blinded to treatment group with 10 5 22Rv1-luciferase cells as described previously. 38 Bioluminescence signal distribution was recorded immediately post-injection to calculate thoracic cavity/whole body (T/WB) ratios as an indicator of injection success and was followed weekly using bioluminescence imaging on an IVIS100 (Caliper Life Sciences, Mountain View, CA) as described previously.
38
Tumor distribution, growth rate analysis and survival. Mouse body weight was measured weekly to monitor general health status. A mouse was euthanatized when it reached clinical endpoints such as >15% body weight loss. We measured thoracic/ whole body (T/WB) ratio and whole body tumor growth rates as described previously. 38 Briefly, for whole body tumor burden, we placed a rectangular region of interest (ROI) around the dorsal and ventral images of each mouse and quantified total flux using Living Image Software v2.50 (Caliper Life Sciences) with the units of photons/sec/cm 2 /sr. We then summed the dorsal and ventral values and plotted weekly for each animal. Organ-specific tumor growth rates were measured as follows: With the minimum signal threshold set to 1% of the maximum, we placed a circular ROI around the specific organ site (e.g., bone, liver or adrenal gland) to be measured for each weekly image and quantified total photon flux using Living Image software with the units of photons/sec. The values were plotted weekly for each animal. Organ sites were selected for this analysis only if the bioluminescent signal was clearly distinguishable from other tumor sites within that same animal and we used ex vivo BLI to positively identify organ sites bearing 22Rv1 tumors. We performed a Kaplan-Meier analysis of survival using GraphPad Prism 4 on the basis that day 0 was the day of intracardiac injections and the endpoint was the day of euthanasia as determined by >15% body weight loss, hind limb paralysis, fracture or unanticipated death. We preformed two separate experiments (11 and 12 mice in each group, respectively) comparing vehicle and atrasentan treated mice and pooled the data for analysis. Metastatic sites were confirmed by gross inspection at necropsy.
Statistical analysis. For whole body tumor burden and tissue specific tumor growth, we performed a two-tailed Student's t-test. For tumor distribution and Kaplan-Meier survival analysis, we performed a chi-square test. Values were considered statistically significant at p < 0.05. tentative at present. 36 Our data is consistent with the notion that ETA antagonism may have significantly inhibited the growth of some of the existing bone metastases, which may contribute to a survival advantage, but a lack of efficacy against tumor growth in soft tissues may have resulted in disease progression. Differential responses of individual tumors may be due to different levels of ET-1 in the tumor microenvironment as suggested by our previous studies. 31 While is it is possible that these differences may also be accounted for by the differences in the pharmacology of the compounds employed in these studies, with careful patient selection criteria, ETA antagonism may ultimately produce a survival benefit in advanced prostate cancer. It remains to be determined, however, whether an agent effective against bone metastasis only will provide a survival benefit in patients with systemic disease. The model described here will be useful in unraveling the complex and incompletely understood role of ET-1 in prostate cancer metastasis.
Materials and Methods
Cell lines. 22Rv1 human prostatic adenocarcinoma cells were obtained directly from the ATCC. Cell lines were stably transduced with a luciferase-expressing retroviral vector and were grown in the ATCC recommended medium (GIBCO, Rockville, MD) supplemented with 10% FBS (HyClone, Logan, UT) and 1 mM non-essential amino acids (GIBCO) as described previously. 38 All cells were grown at 37°C and 5% CO 2 . In vitro cell growth analysis. Drug treatment and metastasis model. We performed all procedures involving animals according to The University of Iowa Animal Care and Use Committee policies. For drug treatment, we used an oral dosing protocol which had previously demonstrated pharmacologically active levels of plasma atrasentan. 17, 46 30 mg atrasentan was dissolved by sonication in 30 ml of 0.125 MNaHCO 3 , pH 8.5 for 15 min. Once dissolved, atrasentan was then added to a solution containing 2.5% glucose (dextrose) dissolved in water. Vehicle was prepared as described above without atrasentan addition. Mice were randomized into two groups and atrasentan (∼10 mg/kg/day) and vehicle were orally administered through drinking water for 3 d prior to tumor cell injection. Drug
